CA2767028A1 - Procedes et compositions destines a detecter un materiel genetique - Google Patents

Info

Publication number

CA2767028A1

CA2767028A1 CA2767028A CA2767028A CA2767028A1 CA 2767028 A1 CA2767028 A1 CA 2767028A1 CA 2767028 A CA2767028 A CA 2767028A CA 2767028 A CA2767028 A CA 2767028A CA 2767028 A1 CA2767028 A1 CA 2767028A1

Authority

CA

Canada

Prior art keywords

ligation

probe

target polynucleotide

probes

chromosome

Prior art date

2009-11-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 247
• 239000000203 mixture Substances 0.000 title claims abstract description 106
• 108090000623 proteins and genes Proteins 0.000 title claims description 51
• 102000004169 proteins and genes Human genes 0.000 title claims description 38
• 102000040430 polynucleotide Human genes 0.000 claims abstract description 198
• 108091033319 polynucleotide Proteins 0.000 claims abstract description 198
• 239000002157 polynucleotide Substances 0.000 claims abstract description 198
• 230000001605 fetal effect Effects 0.000 claims abstract description 144
• 230000002068 genetic effect Effects 0.000 claims abstract description 98
• 230000008774 maternal effect Effects 0.000 claims abstract description 88
• 230000005856 abnormality Effects 0.000 claims abstract description 20
• 239000000523 sample Substances 0.000 claims description 698
• 238000006243 chemical reaction Methods 0.000 claims description 196
• 210000000349 chromosome Anatomy 0.000 claims description 167
• 230000003321 amplification Effects 0.000 claims description 58
• 238000003199 nucleic acid amplification method Methods 0.000 claims description 58
• 108091034117 Oligonucleotide Proteins 0.000 claims description 57
• 208000036878 aneuploidy Diseases 0.000 claims description 48
• 231100001075 aneuploidy Toxicity 0.000 claims description 44
• 239000002773 nucleotide Substances 0.000 claims description 42
• 125000003729 nucleotide group Chemical group 0.000 claims description 42
• 230000027455 binding Effects 0.000 claims description 40
• 239000003094 microcapsule Substances 0.000 claims description 37
• 238000005192 partition Methods 0.000 claims description 31
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 30
• 239000012071 phase Substances 0.000 claims description 29
• 239000003795 chemical substances by application Substances 0.000 claims description 28
• 230000008685 targeting Effects 0.000 claims description 26
• 102000004190 Enzymes Human genes 0.000 claims description 21
• 108090000790 Enzymes Proteins 0.000 claims description 21
• 230000011664 signaling Effects 0.000 claims description 21
• 238000012360 testing method Methods 0.000 claims description 19
• 239000012530 fluid Substances 0.000 claims description 18
• 208000026350 Inborn Genetic disease Diseases 0.000 claims description 16
• 239000011324 bead Substances 0.000 claims description 16
• 238000003776 cleavage reaction Methods 0.000 claims description 16
• 208000016361 genetic disease Diseases 0.000 claims description 16
• 230000007017 scission Effects 0.000 claims description 16
• 238000009396 hybridization Methods 0.000 claims description 15
• 230000002255 enzymatic effect Effects 0.000 claims description 14
• 238000010438 heat treatment Methods 0.000 claims description 14
• 238000000638 solvent extraction Methods 0.000 claims description 13
• 108091008146 restriction endonucleases Proteins 0.000 claims description 11
• 102000006943 Uracil-DNA Glycosidase Human genes 0.000 claims description 9
• 108010072685 Uracil-DNA Glycosidase Proteins 0.000 claims description 9
• 239000004094 surface-active agent Substances 0.000 claims description 9
• 210000001766 X chromosome Anatomy 0.000 claims description 8
• 238000004422 calculation algorithm Methods 0.000 claims description 7
• 239000003550 marker Substances 0.000 claims description 7
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 6
• 125000000129 anionic group Chemical group 0.000 claims description 6
• 230000002759 chromosomal effect Effects 0.000 claims description 6
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 6
• 230000008569 process Effects 0.000 claims description 6
• 150000003863 ammonium salts Chemical group 0.000 claims description 3
• 230000001413 cellular effect Effects 0.000 claims description 3
• 238000006911 enzymatic reaction Methods 0.000 claims description 3
• 239000007790 solid phase Substances 0.000 claims description 3
• 239000007864 aqueous solution Substances 0.000 claims description 2
• NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 2
• 239000011325 microbead Substances 0.000 claims 1
• 238000001514 detection method Methods 0.000 abstract description 79
• 210000004369 blood Anatomy 0.000 abstract description 40
• 239000008280 blood Substances 0.000 abstract description 40
• 239000000463 material Substances 0.000 abstract description 14
• 238000003745 diagnosis Methods 0.000 abstract 1
• 108020004414 DNA Proteins 0.000 description 222
• 239000013615 primer Substances 0.000 description 119
• 238000003752 polymerase chain reaction Methods 0.000 description 76
• 150000007523 nucleic acids Chemical class 0.000 description 59
• 102000039446 nucleic acids Human genes 0.000 description 58
• 108020004707 nucleic acids Proteins 0.000 description 58
• 239000000047 product Substances 0.000 description 58
• 210000004027 cell Anatomy 0.000 description 40
• 238000011304 droplet digital PCR Methods 0.000 description 38
• 239000003921 oil Substances 0.000 description 34
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
• 210000002381 plasma Anatomy 0.000 description 32
• 208000037516 chromosome inversion disease Diseases 0.000 description 28
• 210000001519 tissue Anatomy 0.000 description 27
• 108060002716 Exonuclease Proteins 0.000 description 25
• 102000013165 exonuclease Human genes 0.000 description 25
• 239000012634 fragment Substances 0.000 description 22
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 21
• 239000002751 oligonucleotide probe Substances 0.000 description 21
• -1 hemachromatosis Proteins 0.000 description 19
• 239000011550 stock solution Substances 0.000 description 19
• 230000000295 complement effect Effects 0.000 description 18
• 208000037280 Trisomy Diseases 0.000 description 17
• 239000000839 emulsion Substances 0.000 description 17
• 238000011282 treatment Methods 0.000 description 17
• 239000004971 Cross linker Substances 0.000 description 16
• 230000000694 effects Effects 0.000 description 15
• 239000008346 aqueous phase Substances 0.000 description 14
• 210000003743 erythrocyte Anatomy 0.000 description 14
• 239000007858 starting material Substances 0.000 description 14
• 238000003556 assay Methods 0.000 description 13
• 230000035772 mutation Effects 0.000 description 13
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
• 238000000137 annealing Methods 0.000 description 12
• 239000003086 colorant Substances 0.000 description 12
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
• 239000000975 dye Substances 0.000 description 12
• 238000005259 measurement Methods 0.000 description 12
• 230000035945 sensitivity Effects 0.000 description 12
• 239000000243 solution Substances 0.000 description 12
• 108700028369 Alleles Proteins 0.000 description 11
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 11
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 11
• 210000003754 fetus Anatomy 0.000 description 11
• 230000001965 increasing effect Effects 0.000 description 11
• 210000001161 mammalian embryo Anatomy 0.000 description 11
• 238000007792 addition Methods 0.000 description 10
• 238000002474 experimental method Methods 0.000 description 10
• 238000002844 melting Methods 0.000 description 10
• 230000008018 melting Effects 0.000 description 10
• 238000000926 separation method Methods 0.000 description 10
• 102000053602 DNA Human genes 0.000 description 9
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 230000006037 cell lysis Effects 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 230000007614 genetic variation Effects 0.000 description 8
• 108020004999 messenger RNA Proteins 0.000 description 8
• 201000010374 Down Syndrome Diseases 0.000 description 7
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
• 238000013459 approach Methods 0.000 description 7
• 239000012472 biological sample Substances 0.000 description 7
• 238000005119 centrifugation Methods 0.000 description 7
• 230000000875 corresponding effect Effects 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 239000007850 fluorescent dye Substances 0.000 description 7
• 239000006228 supernatant Substances 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• 206010010356 Congenital anomaly Diseases 0.000 description 6
• 206010011878 Deafness Diseases 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 102100034343 Integrase Human genes 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 239000008366 buffered solution Substances 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 238000004581 coalescence Methods 0.000 description 6
• 239000002299 complementary DNA Substances 0.000 description 6
• 230000029087 digestion Effects 0.000 description 6
• 238000009826 distribution Methods 0.000 description 6
• 239000000499 gel Substances 0.000 description 6
• 208000016354 hearing loss disease Diseases 0.000 description 6
• 238000007834 ligase chain reaction Methods 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 229910001629 magnesium chloride Inorganic materials 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 239000002987 primer (paints) Substances 0.000 description 6
• 238000012545 processing Methods 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 108010068698 spleen exonuclease Proteins 0.000 description 6
• 208000011580 syndromic disease Diseases 0.000 description 6
• 230000005945 translocation Effects 0.000 description 6
• 108010017826 DNA Polymerase I Proteins 0.000 description 5
• 102000004594 DNA Polymerase I Human genes 0.000 description 5
• 108090000364 Ligases Proteins 0.000 description 5
• 102000003960 Ligases Human genes 0.000 description 5
• 108091028043 Nucleic acid sequence Proteins 0.000 description 5
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
• 108010006785 Taq Polymerase Proteins 0.000 description 5
• 206010044688 Trisomy 21 Diseases 0.000 description 5
• 201000010099 disease Diseases 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 238000000605 extraction Methods 0.000 description 5
• 238000001917 fluorescence detection Methods 0.000 description 5
• 238000011534 incubation Methods 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 102000054765 polymorphisms of proteins Human genes 0.000 description 5
• 229920001184 polypeptide Polymers 0.000 description 5
• 230000035935 pregnancy Effects 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 102000004196 processed proteins & peptides Human genes 0.000 description 5
• 235000018102 proteins Nutrition 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 210000003765 sex chromosome Anatomy 0.000 description 5
• 241000894007 species Species 0.000 description 5
• ZRLNBWWGLOPJIC-PYQRSULMSA-N A'-neogammacerane Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CCC(C)(C)[C@@H]1CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1C(C)C ZRLNBWWGLOPJIC-PYQRSULMSA-N 0.000 description 4
• 208000035657 Abasia Diseases 0.000 description 4
• 201000006360 Edwards syndrome Diseases 0.000 description 4
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
• 208000009292 Hemophilia A Diseases 0.000 description 4
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
• 201000009928 Patau syndrome Diseases 0.000 description 4
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 4
• 206010044686 Trisomy 13 Diseases 0.000 description 4
• 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 4
• 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 4
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 230000001133 acceleration Effects 0.000 description 4
• 230000003322 aneuploid effect Effects 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 239000002981 blocking agent Substances 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 210000004252 chorionic villi Anatomy 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 210000003917 human chromosome Anatomy 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 238000002156 mixing Methods 0.000 description 4
• 208000030454 monosomy Diseases 0.000 description 4
• 239000002853 nucleic acid probe Substances 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 210000005259 peripheral blood Anatomy 0.000 description 4
• 239000011886 peripheral blood Substances 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 208000022587 qualitative or quantitative defects of dystrophin Diseases 0.000 description 4
• 239000011541 reaction mixture Substances 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 206010053884 trisomy 18 Diseases 0.000 description 4
• JJUBFBTUBACDHW-UHFFFAOYSA-N 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol Chemical compound OCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F JJUBFBTUBACDHW-UHFFFAOYSA-N 0.000 description 3
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 3
• 206010000234 Abortion spontaneous Diseases 0.000 description 3
• 108010063905 Ampligase Proteins 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 102100022641 Coagulation factor IX Human genes 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 208000032170 Congenital Abnormalities Diseases 0.000 description 3
• 108010053770 Deoxyribonucleases Proteins 0.000 description 3
• 102000016911 Deoxyribonucleases Human genes 0.000 description 3
• AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 108010042407 Endonucleases Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 3
• 102100029075 Exonuclease 1 Human genes 0.000 description 3
• 108010054218 Factor VIII Proteins 0.000 description 3
• 102000001690 Factor VIII Human genes 0.000 description 3
• 108091092584 GDNA Proteins 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 102000010029 Homer Scaffolding Proteins Human genes 0.000 description 3
• 108010077223 Homer Scaffolding Proteins Proteins 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 238000012408 PCR amplification Methods 0.000 description 3
• 239000012807 PCR reagent Substances 0.000 description 3
• 108020004459 Small interfering RNA Proteins 0.000 description 3
• 239000000654 additive Substances 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 description 3
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 3
• 230000007698 birth defect Effects 0.000 description 3
• 210000000601 blood cell Anatomy 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229960005069 calcium Drugs 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 235000001465 calcium Nutrition 0.000 description 3
• 238000001816 cooling Methods 0.000 description 3
• 231100000895 deafness Toxicity 0.000 description 3
• 238000004925 denaturation Methods 0.000 description 3
• 230000036425 denaturation Effects 0.000 description 3
• 238000007847 digital PCR Methods 0.000 description 3
• 238000010252 digital analysis Methods 0.000 description 3
• 230000005670 electromagnetic radiation Effects 0.000 description 3
• 210000002919 epithelial cell Anatomy 0.000 description 3
• 238000001704 evaporation Methods 0.000 description 3
• 230000008020 evaporation Effects 0.000 description 3
• 108010052305 exodeoxyribonuclease III Proteins 0.000 description 3
• 229960000301 factor viii Drugs 0.000 description 3
• 210000004700 fetal blood Anatomy 0.000 description 3
• 238000005189 flocculation Methods 0.000 description 3
• 230000016615 flocculation Effects 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 230000010370 hearing loss Effects 0.000 description 3
• 231100000888 hearing loss Toxicity 0.000 description 3
• 238000007849 hot-start PCR Methods 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 238000009830 intercalation Methods 0.000 description 3
• 238000007169 ligase reaction Methods 0.000 description 3
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 3
• 108091070501 miRNA Proteins 0.000 description 3
• 239000002679 microRNA Substances 0.000 description 3
• 208000015994 miscarriage Diseases 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 210000005087 mononuclear cell Anatomy 0.000 description 3
• 210000002826 placenta Anatomy 0.000 description 3
• 238000011002 quantification Methods 0.000 description 3
• 238000003753 real-time PCR Methods 0.000 description 3
• 239000013074 reference sample Substances 0.000 description 3
• 208000000995 spontaneous abortion Diseases 0.000 description 3
• 238000005382 thermal cycling Methods 0.000 description 3
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
• COBAOGWDMNPNSV-UHFFFAOYSA-N 2-aminopurine-6-thione Chemical class NC1=NC(=S)C2=NC=NC2=N1 COBAOGWDMNPNSV-UHFFFAOYSA-N 0.000 description 2
• 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 2
• JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 2
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 2
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
• 102100032187 Androgen receptor Human genes 0.000 description 2
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 2
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 208000031404 Chromosome Aberrations Diseases 0.000 description 2
• 102100026735 Coagulation factor VIII Human genes 0.000 description 2
• 108010069156 Connexin 26 Proteins 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• 230000006820 DNA synthesis Effects 0.000 description 2
• NPOJQCVWMSKXDN-UHFFFAOYSA-N Dacthal Chemical compound COC(=O)C1=C(Cl)C(Cl)=C(C(=O)OC)C(Cl)=C1Cl NPOJQCVWMSKXDN-UHFFFAOYSA-N 0.000 description 2
• 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
• 230000010777 Disulfide Reduction Effects 0.000 description 2
• 102100037707 Down syndrome critical region protein 4 Human genes 0.000 description 2
• 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
• 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 2
• 102000004533 Endonucleases Human genes 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 101150104226 F8 gene Proteins 0.000 description 2
• 201000003542 Factor VIII deficiency Diseases 0.000 description 2
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
• 102100037156 Gap junction beta-2 protein Human genes 0.000 description 2
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
• 208000031220 Hemophilia Diseases 0.000 description 2
• 101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 2
• 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
• 101000880955 Homo sapiens Down syndrome critical region protein 4 Proteins 0.000 description 2
• 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 2
• 208000027747 Kennedy disease Diseases 0.000 description 2
• 208000017924 Klinefelter Syndrome Diseases 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 108091092878 Microsatellite Proteins 0.000 description 2
• 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 2
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
• 208000009905 Neurofibromatoses Diseases 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• 201000011252 Phenylketonuria Diseases 0.000 description 2
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
• 108010010677 Phosphodiesterase I Proteins 0.000 description 2
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 2
• 108020005115 Pyruvate Kinase Proteins 0.000 description 2
• 238000011529 RT qPCR Methods 0.000 description 2
• 102000006382 Ribonucleases Human genes 0.000 description 2
• 108010083644 Ribonucleases Proteins 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• 208000022292 Tay-Sachs disease Diseases 0.000 description 2
• 208000035199 Tetraploidy Diseases 0.000 description 2
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
• 108020004566 Transfer RNA Proteins 0.000 description 2
• 208000026487 Triploidy Diseases 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 206010062757 Trisomy 15 Diseases 0.000 description 2
• 208000026928 Turner syndrome Diseases 0.000 description 2
• 208000014769 Usher Syndromes Diseases 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 229930003448 Vitamin K Natural products 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 238000002669 amniocentesis Methods 0.000 description 2
• 210000004381 amniotic fluid Anatomy 0.000 description 2
• 239000003945 anionic surfactant Substances 0.000 description 2
• 210000003567 ascitic fluid Anatomy 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 239000002199 base oil Substances 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 239000007795 chemical reaction product Substances 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
• 235000017471 coenzyme Q10 Nutrition 0.000 description 2
• ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
• 229960002887 deanol Drugs 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 239000005547 deoxyribonucleotide Substances 0.000 description 2
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 238000006073 displacement reaction Methods 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 230000006862 enzymatic digestion Effects 0.000 description 2
• 238000012869 ethanol precipitation Methods 0.000 description 2
• 208000032291 genetic form combined pituitary hormone deficiencies Diseases 0.000 description 2
• 229960000587 glutaral Drugs 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 208000009429 hemophilia B Diseases 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
• 238000011901 isothermal amplification Methods 0.000 description 2
• 210000004880 lymph fluid Anatomy 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 235000001055 magnesium Nutrition 0.000 description 2
• 229940091250 magnesium supplement Drugs 0.000 description 2
• 210000004877 mucosa Anatomy 0.000 description 2
• 238000007838 multiplex ligation-dependent probe amplification Methods 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• 201000004931 neurofibromatosis Diseases 0.000 description 2
• 208000012978 nondisjunction Diseases 0.000 description 2
• 201000003738 orofaciodigital syndrome VIII Diseases 0.000 description 2
• 201000009958 panhypopituitarism Diseases 0.000 description 2
• 239000013610 patient sample Substances 0.000 description 2
• 210000004976 peripheral blood cell Anatomy 0.000 description 2
• 229940049953 phenylacetate Drugs 0.000 description 2
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
• 230000003169 placental effect Effects 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 229920001993 poloxamer 188 Polymers 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 238000003793 prenatal diagnosis Methods 0.000 description 2
• 150000003141 primary amines Chemical class 0.000 description 2
• 238000010791 quenching Methods 0.000 description 2
• 230000000171 quenching effect Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 238000005070 sampling Methods 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
• 208000027223 tetraploidy syndrome Diseases 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 229940035893 uracil Drugs 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 238000010200 validation analysis Methods 0.000 description 2
• 235000019156 vitamin B Nutrition 0.000 description 2
• 239000011720 vitamin B Substances 0.000 description 2
• 235000019168 vitamin K Nutrition 0.000 description 2
• 239000011712 vitamin K Substances 0.000 description 2
• 150000003721 vitamin K derivatives Chemical class 0.000 description 2
• 229940046010 vitamin k Drugs 0.000 description 2
• JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• NMOVJBAGBXIKCG-VKAVYKQESA-N (3z)-n-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidoyl chloride Chemical compound C1CCCCN1CC(O)CO\N=C(/Cl)C1=CC=CN=C1 NMOVJBAGBXIKCG-VKAVYKQESA-N 0.000 description 1
• IYVCXLAGSZWAEQ-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8,8a-octadecafluoronaphthalene;1-[1,2,2,3,3,4,5,5,6,6-decafluoro-4-(trifluoromethyl)cyclohexyl]-2,2,3,3,4,4,5,5,6,6-decafluoropiperidine Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C21F.FC1(F)C(F)(F)C(C(F)(F)F)(F)C(F)(F)C(F)(F)C1(F)N1C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F IYVCXLAGSZWAEQ-UHFFFAOYSA-N 0.000 description 1
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
• PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
• PJDOLCGOTSNFJM-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctan-1-ol Chemical compound OCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F PJDOLCGOTSNFJM-UHFFFAOYSA-N 0.000 description 1
• GFVZMGHCWGEFQF-UHFFFAOYSA-N 2-amino-1h-pyrimidine-6-thione Chemical class NC1=NC=CC(=S)N1 GFVZMGHCWGEFQF-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
• MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
• HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
• ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
• ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
• DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical class NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
• 229960005508 8-azaguanine Drugs 0.000 description 1
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
• 208000008190 Agammaglobulinemia Diseases 0.000 description 1
• 201000011374 Alagille syndrome Diseases 0.000 description 1
• 201000002434 Alpha-thalassemia-X-linked intellectual disability syndrome Diseases 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 108091093088 Amplicon Proteins 0.000 description 1
• 206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 description 1
• 208000009575 Angelman syndrome Diseases 0.000 description 1
• 241001244729 Apalis Species 0.000 description 1
• 206010063847 Arachnodactyly Diseases 0.000 description 1
• JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
• 102000007370 Ataxin2 Human genes 0.000 description 1
• 108010032951 Ataxin2 Proteins 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000018311 Autosomal trisomy Diseases 0.000 description 1
• 208000034076 BOR syndrome Diseases 0.000 description 1
• 102000036365 BRCA1 Human genes 0.000 description 1
• 108700020463 BRCA1 Proteins 0.000 description 1
• 101150072950 BRCA1 gene Proteins 0.000 description 1
• 102000052609 BRCA2 Human genes 0.000 description 1
• 108700020462 BRCA2 Proteins 0.000 description 1
• 108020000946 Bacterial DNA Proteins 0.000 description 1
• 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
• 201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 description 1
• 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
• KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
• 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101150008921 Brca2 gene Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 1
• 208000010482 CADASIL Diseases 0.000 description 1
• RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
• 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
• 208000022526 Canavan disease Diseases 0.000 description 1
• 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 1
• 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 description 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
• 201000006892 Charcot-Marie-Tooth disease type 1 Diseases 0.000 description 1
• 208000031874 Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy Diseases 0.000 description 1
• 206010008723 Chondrodystrophy Diseases 0.000 description 1
• 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
• 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
• 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
• 108020004638 Circular DNA Proteins 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 208000010200 Cockayne syndrome Diseases 0.000 description 1
• ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
• 206010049889 Craniosynostosis Diseases 0.000 description 1
• 206010011777 Cystinosis Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108050009160 DNA polymerase 1 Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
• 208000014094 Dystonic disease Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• 208000005917 Exostoses Diseases 0.000 description 1
• 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
• 208000035126 Facies Diseases 0.000 description 1
• 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 1
• 108010076282 Factor IX Proteins 0.000 description 1
• 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
• 206010055690 Foetal death Diseases 0.000 description 1
• 208000001914 Fragile X syndrome Diseases 0.000 description 1
• 208000024412 Friedreich ataxia Diseases 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 208000001905 GM2 Gangliosidoses Diseases 0.000 description 1
• 208000027472 Galactosemias Diseases 0.000 description 1
• 208000015872 Gaucher disease Diseases 0.000 description 1
• 239000009429 Ginkgo biloba extract Substances 0.000 description 1
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000018565 Hemochromatosis Diseases 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
• 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 description 1
• 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• 102000016871 Hexosaminidase A Human genes 0.000 description 1
• 108010053317 Hexosaminidase A Proteins 0.000 description 1
• 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
• 101000590492 Homo sapiens Nuclear fragile X mental retardation-interacting protein 1 Proteins 0.000 description 1
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 206010020608 Hypercoagulation Diseases 0.000 description 1
• 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 1
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 208000007031 Incontinentia pigmenti Diseases 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• 101710203526 Integrase Proteins 0.000 description 1
• 208000028226 Krabbe disease Diseases 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 102000008192 Lactoglobulins Human genes 0.000 description 1
• 108010060630 Lactoglobulins Proteins 0.000 description 1
• 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
• 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
• 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
• 206010048911 Lissencephaly Diseases 0.000 description 1
• 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
• 208000001826 Marfan syndrome Diseases 0.000 description 1
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
• 208000036626 Mental retardation Diseases 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 1
• 208000002693 Multiple Abnormalities Diseases 0.000 description 1
• 208000003452 Multiple Hereditary Exostoses Diseases 0.000 description 1
• 206010073149 Multiple endocrine neoplasia Type 2 Diseases 0.000 description 1
• 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
• 101500006448 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) Endonuclease PI-MboI Proteins 0.000 description 1
• 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
• 206010068871 Myotonic dystrophy Diseases 0.000 description 1
• KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
• BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
• 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
• 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 208000010577 Niemann-Pick disease type C Diseases 0.000 description 1
• 208000004485 Nijmegen breakage syndrome Diseases 0.000 description 1
• 108091092724 Noncoding DNA Proteins 0.000 description 1
• 208000025464 Norrie disease Diseases 0.000 description 1
• 102100032428 Nuclear fragile X mental retardation-interacting protein 1 Human genes 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 1
• 201000011392 Pallister-Hall syndrome Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 206010033892 Paraplegia Diseases 0.000 description 1
• 208000027089 Parkinsonian disease Diseases 0.000 description 1
• 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
• 208000004843 Pendred Syndrome Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 1
• 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
• 102000004576 Placental Lactogen Human genes 0.000 description 1
• 108010003044 Placental Lactogen Proteins 0.000 description 1
• 239000000381 Placental Lactogen Substances 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 239000004721 Polyphenylene oxide Substances 0.000 description 1
• 208000020584 Polyploidy Diseases 0.000 description 1
• 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
• 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
• KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 239000013616 RNA primer Substances 0.000 description 1
• 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 101150025323 SCLT1 gene Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 208000037492 Sex Chromosome Aberrations Diseases 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 201000007410 Smith-Lemli-Opitz syndrome Diseases 0.000 description 1
• 229920002385 Sodium hyaluronate Polymers 0.000 description 1
• 208000032930 Spastic paraplegia Diseases 0.000 description 1
• 201000003622 Spinocerebellar ataxia type 2 Diseases 0.000 description 1
• 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
• 201000003620 Spinocerebellar ataxia type 6 Diseases 0.000 description 1
• 241001613917 Staphylococcus virus 29 Species 0.000 description 1
• 208000027077 Stickler syndrome Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 239000004809 Teflon Substances 0.000 description 1
• 229920006362 Teflon® Polymers 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 229920002359 Tetronic® Polymers 0.000 description 1
• 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
• 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 206010071762 Trisomy 14 Diseases 0.000 description 1
• 206010053871 Trisomy 8 Diseases 0.000 description 1
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
• 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 1
• 229920001807 Urea-formaldehyde Polymers 0.000 description 1
• 229930003270 Vitamin B Natural products 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 206010049644 Williams syndrome Diseases 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 description 1
• 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 1
• 201000011212 X-linked dilated cardiomyopathy Diseases 0.000 description 1
• 101000909800 Xenopus laevis Probable N-acetyltransferase camello Proteins 0.000 description 1
• 210000002593 Y chromosome Anatomy 0.000 description 1
• 208000008919 achondroplasia Diseases 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 235000013793 astaxanthin Nutrition 0.000 description 1
• MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
• 229940022405 astaxanthin Drugs 0.000 description 1
• 239000001168 astaxanthin Substances 0.000 description 1
• 208000025341 autosomal recessive disease Diseases 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 208000005980 beta thalassemia Diseases 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 229950002409 bimoclomol Drugs 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 239000003876 biosurfactant Substances 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 206010071434 biotinidase deficiency Diseases 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 206010071135 branchio-oto-renal syndrome Diseases 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000004227 calcium gluconate Substances 0.000 description 1
• 235000013927 calcium gluconate Nutrition 0.000 description 1
• 229960004494 calcium gluconate Drugs 0.000 description 1
• NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 201000004006 camptodactyly-arthropathy-coxa vara-pericarditis syndrome Diseases 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 1
• 210000003756 cervix mucus Anatomy 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 150000001841 cholesterols Chemical class 0.000 description 1
• WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 229960001284 citicoline Drugs 0.000 description 1
• GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000027832 depurination Effects 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 229940064790 dilantin Drugs 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 239000003814 drug Substances 0.000 description 1
• 208000010118 dystonia Diseases 0.000 description 1
• 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 208000007150 epidermolysis bullosa simplex Diseases 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 210000000416 exudates and transudate Anatomy 0.000 description 1
• 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 1
• 108010091897 factor V Leiden Proteins 0.000 description 1
• 229960004222 factor ix Drugs 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 229960004279 formaldehyde Drugs 0.000 description 1
• SLGWESQGEUXWJQ-UHFFFAOYSA-N formaldehyde;phenol Chemical compound O=C.OC1=CC=CC=C1 SLGWESQGEUXWJQ-UHFFFAOYSA-N 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 238000001641 gel filtration chromatography Methods 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 229940068052 ginkgo biloba extract Drugs 0.000 description 1
• 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229960001031 glucose Drugs 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
• 210000002768 hair cell Anatomy 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 238000003505 heat denaturation Methods 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
• 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
• 235000020256 human milk Nutrition 0.000 description 1
• 210000004251 human milk Anatomy 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 150000002443 hydroxylamines Chemical class 0.000 description 1
• 239000000819 hypertonic solution Substances 0.000 description 1
• 229940021223 hypertonic solution Drugs 0.000 description 1
• 201000010072 hypochondroplasia Diseases 0.000 description 1
• 206010021198 ichthyosis Diseases 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 229960000367 inositol Drugs 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000012977 invasive surgical procedure Methods 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000006443 lactic acidosis Diseases 0.000 description 1
• 150000002605 large molecules Chemical class 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 208000014817 lissencephaly spectrum disease Diseases 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 238000007837 multiplex assay Methods 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 229960002259 nedocromil sodium Drugs 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 238000007857 nested PCR Methods 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 208000002761 neurofibromatosis 2 Diseases 0.000 description 1
• 208000022032 neurofibromatosis type 2 Diseases 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 208000000736 oculocutaneous albinism type 1 Diseases 0.000 description 1
• 230000034004 oogenesis Effects 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 102000045222 parkin Human genes 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 208000036897 pentasomy Diseases 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 229920001568 phenolic resin Polymers 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000570 polyether Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 230000037048 polymerization activity Effects 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• ODGAOXROABLFNM-UHFFFAOYSA-N polynoxylin Chemical compound O=C.NC(N)=O ODGAOXROABLFNM-UHFFFAOYSA-N 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 238000013139 quantization Methods 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000012340 reverse transcriptase PCR Methods 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 238000007142 ring opening reaction Methods 0.000 description 1
• 238000005096 rolling process Methods 0.000 description 1
• 101150116497 sacm1l gene Proteins 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 108700004121 sarkosyl Proteins 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 238000011896 sensitive detection Methods 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 238000007860 single-cell PCR Methods 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 229940010747 sodium hyaluronate Drugs 0.000 description 1
• YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 230000021595 spermatogenesis Effects 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 1
• 201000003632 spinocerebellar ataxia type 7 Diseases 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 208000002254 stillbirth Diseases 0.000 description 1
• 231100000537 stillbirth Toxicity 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 210000004895 subcellular structure Anatomy 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 229960004793 sucrose Drugs 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 229960003080 taurine Drugs 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• 229940090016 tegretol Drugs 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
• 208000011908 tetrasomy Diseases 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical class O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
• 201000005665 thrombophilia Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
• 206010044689 trisomy 22 Diseases 0.000 description 1
• 208000026485 trisomy X Diseases 0.000 description 1
• 208000034298 trisomy chromosome 8 Diseases 0.000 description 1
• WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 229940035936 ubiquinone Drugs 0.000 description 1
• 210000001644 umbilical artery Anatomy 0.000 description 1
• 210000003954 umbilical cord Anatomy 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 201000000866 velocardiofacial syndrome Diseases 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 150000003712 vitamin E derivatives Chemical class 0.000 description 1
• 235000019143 vitamin K2 Nutrition 0.000 description 1
• 239000011728 vitamin K2 Substances 0.000 description 1
• 229940046001 vitamin b complex Drugs 0.000 description 1
• 229940041603 vitamin k 3 Drugs 0.000 description 1
• 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
• 239000007762 w/o emulsion Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000036266 weeks of gestation Effects 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011592 zinc chloride Substances 0.000 description 1
• 235000005074 zinc chloride Nutrition 0.000 description 1
• 239000011746 zinc citrate Substances 0.000 description 1
• 235000006076 zinc citrate Nutrition 0.000 description 1
• 229940068475 zinc citrate Drugs 0.000 description 1
• 229940061639 zonegran Drugs 0.000 description 1
• UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1